Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity.

the injection of luteinising hormone releasing hormone is of considerable interest.At three months this rise was absent in samples taken one hour after injection but it was seen in all patients at six months and was more appreciable at 12 months.The mechanism for the rise is unclear but it may arise from either a change in the receptors that makes them unable to accept the analogue or an acceleration in regulation by the receptors.Further studies are needed to explain the mechanism.Rises in testosterone concentration were seen in only three patients, all of whom developed disease progression.The reason why testosterone concentration failed to rise in all patients may relate to prolonged suppression of testicular activity by the analogue.Daily administration of luteinising hormone releasing hormone analogues is not recommended as a long term treatment for carcinoma of the prostate because of its failure to suppress luteinising hormone and testosterone concentrations.The mechanism for this failure has considerable implications in the long term use of peptide analogues.